August 13, 2024

Josh Mandel-Brehm
Chief Executive Officer
Camp4 Therapeutics Corp
One Kendall Square, Building 1400 West, 3rd Floor
Cambridge, MA 02139

       Re: Camp4 Therapeutics Corp
           Amendment No. 2 to Draft Registration Statement on Form S-1
           Submitted August 2, 2024
           CIK No. 0001736730
Dear Josh Mandel-Brehm:

     We have reviewed your amended registration statement and have the
following
comments.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe a comment applies to your facts
and circumstances
or do not believe an amendment is appropriate, please tell us why in your
response.

       After reviewing any amendment to your registration statement and the
information you
provide in response to this letter, we may have additional comments. Unless we
note otherwise,
any references to prior comments are to comments in our July 14, 2024 letter.

Amendment No. 2 to Draft Registration Statement on Form S-1
Overview, page 1

1.     We note your response to prior comment 1. Please tell us whether you had
material
       research and development expenses relating to the Dravet syndrome
candidate in
       FY2023.
 August 13, 2024
Page 2
License and collaboration agreements
Whitehead Institute patent license agreement, page 132

2.     We note your response to prior comments 22 and 23. Please further revise
your disclosure
       related to the Whitehead agreement to specifically quantify the
potential aggregate
       development milestone payments that may be payable under the terms of
the agreement
       upon the achievement of certain specified contingent events. Also,
revise your description
       of the duration of the royalty term to disclose the number of years
after the first
       commercial sale after which the term might expire.

       Please contact Gary Newberry at 202-551-3761 or Mary Mast at
202-551-3613 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Lauren Sprague Hamill at 303-844-1008 or Joe McCann at 202-551-6262
with any other
questions.



                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Thomas Danielski